Rethinking clinical trial endpoints in myelodysplastic syndromes

Overview of attention for article published in Leukemia, January 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

twitter: 34 X users

Readers on

mendeley: 18 Mendeley

So far, Altmetric has seen 38 X posts from 34 X users, with an upper bound of 209,204 followers.

RT @drsangeetmd: @tomleblancMD @MikkaelSekeres @farrellybros @ramsedhom @DavidSteensma https://t.co/wLRwWHSGxc In that vein 1more by the dy…

@tomleblancMD @MikkaelSekeres @farrellybros @ramsedhom @DavidSteensma https://t.co/wLRwWHSGxc In that vein 1more by the dynamic duo @MikkaelSekeres @DavidSteensma with the 🎥 reference: “This is Spinal tap” compared to #mdssm endpts. The 📑 prompted me t…

RT @Hema_News: Review | Rethinking clinical trial endpoints in myelodysplastic syndromes @ClevelandClinic @DanaFarber @MikkaelSekeres @Davi…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 34 additional X posts.